Literature DB >> 6874860

Determination of sparsomycin in plasma and urine of the dog by means of reversed-phase high-performance liquid chromatography and first pharmacokinetic results.

B Winograd, M J Oosterbaan, E van der Kleijn, R M Liskamp, H C Ottenheijm, D J Wagener.   

Abstract

Sparsomycin--an antibiotic with marked cytostatic activity--was the subject of a clinical Phase I study in 1964. The structure of sparsomycin was elucidated in 1970 and its first total synthesis was reported in 1981. Here we describe a sensitive high-performance liquid chromatographic method of determination. The detection limit was found to be 10 ng/ml of plasma and 20 ng/ml of urine. With this procedure sparsomycin and isosparsomycin can readily be separated. In addition, we performed a first pharmacokinetic study in the dog and found a half-life time t1/2 beta of 1.1 h. Only 25% of the administered dose could be recovered in the urine as sparsomycin. We consider that by now many prerequisites for further preclinical studies have been achieved, and the results of these studies will determine whether sparsomycin deserves reintroduction into clinical use.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6874860     DOI: 10.1016/s0378-4347(00)84353-4

Source DB:  PubMed          Journal:  J Chromatogr


  3 in total

1.  Pharmacokinetics of the antitumor antibiotic n-pentyl-sparsomycin in beagle dogs.

Authors:  Z Zylicz; D J Wagener; M Garzotto; T B Vree; E van der Kleijn; L A van den Broek; H C Ottenheijm
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

2.  Pharmacokinetics and toxicology of sparsomycin in beagle dogs.

Authors:  Z Zylicz; D J Wagener; P Fernandez del Moral; H van Rennes; J M Wessels; B Winograd; E van der Kleijn; T B Vree; U van Haelst; L A van den Broek
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor models.

Authors:  Z Zylicz; D J Wagener; H van Rennes; E van der Kleijn; P Lelieveld; L A van den Broek; H C Ottenheijm
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.